Tempest Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
TPST$0.37+3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $12,606 | $28,476 |
| General and administrative | 13,969 | 13,550 |
| Operating loss | (26,575) | (42,026) |
| Other income (expense), net: | ||
| Interest expense | (207) | (1,316) |
| Interest income and other income (expense), net | 520 | 1,499 |
| Other income (expense), net | 313 | 183 |
| Provision for income taxes | — | — |
| Net loss | $(26,262) | $(41,843) |
| Net loss per share of common stock and pre-funded warrants, basic and diluted(1) | $(6.33) | $(19.50) |
| Weighted-average shares of common stock and pre-funded warrants outstanding, basic and diluted(1) | 4,149,733 | 2,146,276 |
(1) Results, including shares of common stock, have been adjusted to reflect theone-for-thirteen stock split effected in April 2025. See Note 1, Organization and Description of the Business, for details.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.